Success Metrics

Clinical Success Rate
85.2%

Based on 23 completed trials

Completion Rate
85%(23/27)
Active Trials
17(33%)
Results Posted
48%(11 trials)
Terminated
4(8%)

Phase Distribution

Ph early_phase_1
4
8%
Ph phase_3
2
4%
Ph not_applicable
6
12%
Ph phase_1
12
23%
Ph phase_2
13
25%
Ph phase_4
1
2%

Phase Distribution

16

Early Stage

13

Mid Stage

3

Late Stage

Phase Distribution38 total trials
Early Phase 1First-in-human
4(10.5%)
Phase 1Safety & dosage
12(31.6%)
Phase 2Efficacy & side effects
13(34.2%)
Phase 3Large-scale testing
2(5.3%)
Phase 4Post-market surveillance
1(2.6%)
N/ANon-phased studies
6(15.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.1%

23 of 28 finished

Non-Completion Rate

17.9%

5 ended early

Currently Active

17

trials recruiting

Total Trials

52

all time

Status Distribution
Active(21)
Completed(23)
Terminated(5)
Other(3)

Detailed Status

Completed23
Recruiting15
Terminated4
unknown3
Not yet recruiting3
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
52
Active
17
Success Rate
85.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (10.5%)
Phase 112 (31.6%)
Phase 213 (34.2%)
Phase 32 (5.3%)
Phase 41 (2.6%)
N/A6 (15.8%)

Trials by Status

completed2344%
withdrawn12%
enrolling_by_invitation12%
recruiting1529%
unknown36%
terminated48%
not_yet_recruiting36%
active_not_recruiting24%

Recent Activity

Clinical Trials (52)

Showing 20 of 52 trialsScroll for more
NCT06470282Phase 1

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

Recruiting
NCT07588698Phase 2

Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma

Not Yet Recruiting
NCT06474533

Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm

Recruiting
NCT07776353

Understanding New Cachexia Subtypes Through Observational Epidemiological Research

Recruiting
NCT01937117Phase 2

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

Active Not Recruiting
NCT07078604Phase 2

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Recruiting
NCT06675357Phase 2

Using FAPI PET/MRI to Evaluate Prostate Cancer

Recruiting
NCT07604207Early Phase 1

Multi-organ Imaging of Microvascular and Metabolic Function

Not Yet Recruiting
NCT06862856

Flotufolastat F 18 PET in Men With Very Low PSA Recurrence

Recruiting
NCT04716725Phase 2

68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

Terminated
NCT06600880Phase 1

Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

Not Yet Recruiting
NCT07217028Phase 1

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

Recruiting
NCT04895631Phase 3

18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas

Completed
NCT05388006Phase 2

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recruiting
NCT05888532Phase 1

64Cu-GRIP B in Patients With Advanced Malignancies

Recruiting
NCT04044937Phase 2

Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms

Completed
NCT06821646

Investigating the Brain's Physiological Responses in Depression and Autism, Using Transcranial Magnetic Stimulation and Electroencephalography

Enrolling By Invitation
NCT06522932Phase 1

PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy

Recruiting
NCT02904187Not Applicable

Cerebral Activation and Bilateral Stimulation by Cochlear Implantation in Bilateral Deaf Adults

Completed
NCT07218224

Expanded Access:18F-Fluorocholine for the Detection of Parathyroid Adenomas

Unknown

Drug Details

Intervention Type
PROCEDURE
Total Trials
52